Document Detail

Detection of prostate cancer and predicting progression: current and future diagnostic markers.
MedLine Citation:
PMID:  15217924     Owner:  NLM     Status:  MEDLINE    
Carcinoma of the prostate is the second leading cause of male cancer-related death in the United States. Better indicators of prostate cancer presence and progression are needed to avoid unnecessary treatment, predict disease course, and develop more effective therapy. Numerous molecular markers have been described in human serum, urine, seminal fluid, and histological specimens that exhibit varying capacities to detect prostate cancer and predict disease course. However, to date, few of these markers have been adequately validated for clinical use. The purpose of this review is to examine the current status of these markers in prostate cancer and to assess the diagnostic potential for future markers from identified genes and molecules that display loss, mutation, or alteration in expression between tumor and normal prostate tissues. In this review we cite 91 molecular markers that display some level of correlation with prostate cancer presence, disease progression, cancer recurrence, prediction of response to therapy, and/or disease-free survival. We suggest criteria to consider when selecting a marker for further development as a clinical tool and discuss five examples of markers (chromogranin A, glutathione S-transferase pi 1, prostate stem cell antigen, prostate-specific membrane antigen, and telomerase reverse transcriptase) that fulfill some of these criteria. Finally, we discuss how to conduct evaluations of candidate prostate cancer markers and some of the issues involved in the validation process.
James V Tricoli; Mason Schoenfeldt; Barbara A Conley
Related Documents :
16861114 - New insights into prostate cancer biology.
19861534 - Noninvasive multiparametric imaging of metastasis-permissive microenvironments in a hum...
25296354 - Epidermal growth factor receptor (egfr) mutations in lung cancer: preclinical and clini...
12206844 - Prostate cryoablation: a scientific rationale for future modifications.
9364544 - Docetaxel in combination with fluorouracil for advanced solid tumors.
6404154 - A phase i-ii study of continuous 5-day infusion mitomycin-c.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  10     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-06-25     Completed Date:  2005-01-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3943-53     Citation Subset:  IM    
Diagnostics Research Branch, Cancer Diagnosis Program, National Cancer Institute, Rockville, Maryland, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, Surface / biosynthesis
Chromogranin A
Chromogranins / biosynthesis
DNA-Binding Proteins
Disease Progression
Glutamate Carboxypeptidase II / biosynthesis
Glutathione Transferase / biosynthesis
Membrane Glycoproteins / biosynthesis
Neoplasm Proteins / biosynthesis
Prostatic Neoplasms / diagnosis*,  pathology*
Telomerase / biosynthesis
Tumor Markers, Biological*
Reg. No./Substance:
0/Antigens, Surface; 0/Chromogranin A; 0/Chromogranins; 0/DNA-Binding Proteins; 0/Membrane Glycoproteins; 0/Neoplasm Proteins; 0/PSCA protein, human; 0/Tumor Markers, Biological; EC Transferase; EC; EC Carboxypeptidase II; EC carboxypeptidase II, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mesothelin: a new target for immunotherapy.
Next Document:  A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: int...